What You Need to Know
• The Food and Drug Administration’s Pharmacy Compounding Advisory Committee voted to loosen restrictions on peptides.
• The committee’s decision comes despite strong objections from FDA career scientists regarding safety and efficacy.
• The committee voted in favor of four specific peptides: BPC-157, KPV, TB-500, and MOTS-c.
The Food and Drug Administration’s Pharmacy Compounding Advisory Committee voted on Thursday to ease restrictions on certain peptides, despite significant opposition from agency career scientists. Throughout the meeting, FDA scientists raised concerns about the lack of evidence supporting the safety and efficacy of these compounds, which have gained popularity in the wellness industry. The committee endorsed four peptides: BPC-157, KPV, TB-500, and MOTS-c, with further discussions planned for additional peptides. This vote does not grant FDA approval for these peptides but recommends their inclusion on a list of drugs that compounding pharmacies may produce. The final decision will be made by the FDA through a rule proposal.
Why It Matters
The FDA’s decision to consider loosening restrictions on peptides is significant due to the increasing popularity of these compounds in health and wellness circles. Prominent figures, including Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan, have endorsed their use for various health benefits. However, these peptides have largely operated in a gray market, lacking FDA approval and often sold online for “research use only.” The outcome of this advisory committee’s vote may influence the regulation and safety of peptide use in the future, particularly as the wellness industry continues to expand.
Read the Full Story →
